Latest news for Robix EnvirnTech (OTC:ROBXF) Stock

Robix Environmental Technologies Inc is focused on providing oil recovery equipment and oil and gas wastewater treatment products. The company operates in two segments namely Clean Ocean Vessel and Water Treatment Technology. It generates its revenue from Clean Ocean Vessel.

ROBIX ENVIRO TECH ORD by Robix Environmental Technologies, Inc.

Robix Environmental Technologies Inc

<a href="https://truthsocial.com/@realDonaldTrump/112837096247654677" title="https://truthsocial.com/@realDonaldTrump/112837096247654677">https://truthsocial.com/@realDonaldTrump/112837096247654677</a>

News

Politics

General

ISRA

Update On Trump, Netanyahu Meeting; Trump Post On Truth Social, "At the request of Bibi Netanyahu, we have switched this meeting to Friday, July 26th at Mar-a-Lago in Palm Beach, Florida!"

Vertically integrated cannabis company Cannara Biotech Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#TSXV">LOVE</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/LOVFF#OTCQB">LOVFF</a>) (FRA: 8CB0) announced its fiscal third quarter 2024 financial and operating results on Tuesday for the three month period ended May 31, 2024.
Zohar Krivorot, Cannara&#8217;s president and CEO, praised the company's "strong performance," during the period, with net revenues reaching CA$19.5 million ($14.2 million) during the quarter, representing a 22.6% year-over-year increase.
&#8220;Historically, our sales growth has been driven by great customer loyalty and strong demand for our products, amplified by organic word-of-mouth promotion," Krivorot explained. "However, as indicated by our flat quarter-to-quarter results, this can only take us so far. To continue our expansion across the country, we have begun enhancing our sales force and infrastructure."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/38563458/cannara-biotech-reports-51-yoy-revenue-increase-in-q2-wider-net-loss">Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss</a>
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
<ul>
<li>Gross profit, before fair value adjustments, decreased to CA$5.7 million from CA$6.1 million in the prior year's quarter, representing a 6.1% year-over-year decline.</li>
<li>Gross profit percentage before fair value adjustments was 29% compared to 38% in the corresponding quarter of 2023.</li>
<li>Operating income totaled CA$3.6 million compared to CA$4.3 million in the same period of fiscal 2023.</li>
<li>Net income of CA$2 million compared to CA$2.9 million in the prior year's period.</li>
<li>Adjusted EBITDA came in positive at CA$2.8 million, compared to CA$3.9 million adjusted EBITDA gain in the prior year's period.</li>
<li>The company generated operating cash flow amounting to CA$4.3 million compared to CA$2.5 million in the third quarter of last year, representing a year-over-year increase of 72%.</li>
<li>Free cash flow increased to CA$1.2 million from CA$37,000 in the third quarter of 2023.</li>
<li>Generated earnings per share of CA$0.02 compared to CA$0.03 in the prior year's period.</li>
</ul>
<h3 class="wp-block-heading">Q3 2024 Operational Highlights</h3>
<ul>
<li>Expansion in Manitoba, Canada;</li>
<li>Successful launch of three new genetics for Cannara's House of Brands;</li>
<li>Sale of a parcel of land at Valleyfield site;</li>
<li>Cannara enters East Coast recreational market with the 4/20-themed offer with NSLC; and</li>
<li>Continued expansion in Quebec and other provinces.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/02/36979898/cannara-biotech-q1-results-revenue-net-income-and-market-share-up-quarter-also-marks-companys-fir">Cannara Biotech Q1 Results: Revenue, Net Income And Market Share Up, Quarter Also Marks Company&#8217;s First Export Sale</a></li>
</ul>
To learn more about cannabis stocks, come, join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.

Cannabis

Earnings

LOVE

LOVFF

TSXV:LOVE

Cannara Biotech Reports 6% YoY Drop In Q3 Gross Profit, 22% Revenue Increase As It Enhances Sales Force And Infrastructure

Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) goes Uber Technologies, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) way with the latest move.
The ride-hailing company is expanding its services beyond ride-hailing and food delivery by entering Southeast Asia&#8217;s competitive restaurant booking industry.
For comparison, Uber <a target="_blank" href="https://www.benzinga.com/news/earnings/24/05/38699562/ubers-bottomline-takes-a-hit-despite-revenue-uptick-stock-tanks" rel="noreferrer noopener">reported delivery&nbsp;revenue</a> of $3.21 billion, which is up 4% in the first quarter.
Confirming to <a target="_blank" href="https://techcrunch.com/2024/07/23/grab-acquires-singapores-restaurant-reservation-platform-chope/" rel="noreferrer noopener">TechCrunch</a>, Grab acquired the Singapore-based dining reservation platform Chope for an undisclosed amount.
The move aims to differentiate Grab from its competitors and improve margins by expanding its restaurant reservation business.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/24/05/39089311/ubers-asia-peer-grab-taps-openai-to-enhance-app-navigation-and-customer-support" rel="noreferrer noopener">Uber&#8217;s Asia Peer Grab Taps OpenAI to Enhance App Navigation and Customer Support</a>
Grab&#8217;s acquisition of Chope significantly boosts its restaurant booking capabilities. With 13,000 eateries across Singapore, Hong Kong, China, Indonesia, and Thailand, Chope will integrate with Grab&#8217;s existing services, such as HungryGoWhere, acquired in 2022.
Founded in 2011, Chope raised over $64 million from investors, including Ant Group and Singha Ventures.
The acquisition allows Grab to offer enhanced restaurant booking services, distinguishing it from peers like GoTo and Line Man Wongnai.
Grab held $2.1 billion in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38861369/grab-reports-first-quarter-2024-results" rel="noreferrer noopener">cash and equivalents</a> as of March 31.
Grab&#8217;s first-quarter revenue of $653 million (up 24% year-on-year) in the first quarter of 2024 compared to Uber&#8217;s $10.10 billion (up by 15% year-on-year).
Price Action:&nbsp;GRAB shares traded lower by 0.15% at $3.37 at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/02/37034210/grab-and-goto-rekindle-merger-talks-amidst-fierce-competition-report" target="_blank" rel="noreferrer noopener">Grab And GoTo Rekindle Merger Talks Amidst Fierce Competition: Report</a></li>
</ul>
Photo via Shutterstock

Tech

Media

GRAB

UBER

Grab Follows Uber's Lead, Acquires Chope To Expand Into Restaurant Bookings

Goldman Sachs analyst Bonnie Herzog reiterated a <a target="_blank" href="https://www.benzinga.com/quote/KO/analyst-ratings" rel="noreferrer noopener">Neutral rating</a> on the shares of Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>)&nbsp;with a price target of $60.00.
KO delivered an<a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39904801/coca-colas-sweet-surge-q2-earnings-soar-raises-2024-forecasts" rel="noreferrer noopener"> impressive second-quarter top line beat</a>, which coupled with strong gross margin expansion led to an EPS beat at $0.84, opined the analyst.
The analyst was caught surprised with the magnitude of the earnings beat yet again.
The top-line beat was driven by strong price/mix growth of +9% y/y &#8211; ahead of the analyst's estimate, which continues to reflect KO's strong pricing power and impressive revenue growth management capabilities.&nbsp;
Despite some lingering cost pressures and inflation, gross margins expanded ~200bps y/y to 61.4%, with the operating margin also up ~120bps y/y to 32.8%.
Given the strong quarter, KO raised its FY24 guidance for the second time this year, which is very strong compared to its CPG peers, noted the analyst.
The analyst also noted that the top-line organic growth guidance includes the anticipated pricing impact of several markets experiencing intense inflation.
Overall, the analyst considers KO's guidance is reflective of still-resilient consumer elasticities and the company's impressive execution in a challenging operating environment.
The analyst expects ongoing f/x headwinds and tempered reported dollar EPS growth this year could weigh on the stock in the near term.
That said, the analyst continues to see a neutral risk/reward given KO's ongoing litigation with the IRS and potential tax liabilities while KO's exposure to floating rate debt and stepped-up f/x headwinds keeps the analyst on the sidelines.
The analyst's 12-month price target of $60 is based on an equal-weighted P/E of 19.5x and EV/EBITDA of 16.1x, both on the FY25 estimates.
Price Action: KO shares are trading higher by 0.69% at $65.22 at last check Tuesday.
Image via Shutterstock

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

Trading Ideas

Coca-Cola's Revenue And Profit Shows Resilient Growth Amid Inflation: Goldman Sachs

White House Says Biden To Meet With Netanyahu On Thursday

<a href="https://truthsocial.com/@realDonaldTrump/112837026187119625" title="https://truthsocial.com/@realDonaldTrump/112837026187119625">https://truthsocial.com/@realDonaldTrump/112837026187119625</a>

Trump Says He Is Meeting Netanyahu On Thursday, After Previously Announcing They Would Meet On Wednesday

In the last three months, 5 analysts have published ratings on Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Moelis and provided 12-month price targets. The average target is $52.4, accompanied by a high estimate of $61.00 and a low estimate of $47.00. Witnessing a positive shift, the current average has risen by 2.75% from the previous average price target of $51.00.
<img src="https://www.benzinga.com/files/images/story/2024/1721757703_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Moelis's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$61.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$54.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Moelis. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moelis compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Moelis's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Moelis's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Moelis analyst ratings.</a>
<h2>Unveiling the Story Behind Moelis</h2>
Moelis &amp; Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
<h3>Moelis: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Moelis displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 15.79%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 7.62%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.62%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Moelis's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.51% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Moelis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.58.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Moelis: Insights From 5 Financial Analysts

In the last three months, 12 analysts have published ratings on Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Under Armour, presenting an average target of $7.0, a high estimate of $10.00, and a low estimate of $4.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.86%. 
<img src="https://www.benzinga.com/files/images/story/2024/1721757664_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Under Armour among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kimberly Greenberger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$4.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$6.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Will Gaertner</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Will Gaertner</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Under Armour. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Under Armour compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Under Armour's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Under Armour's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Under Armour analyst ratings.</a>
<h2>Discovering Under Armour: A Closer Look</h2>
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and other regions. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
<h3>Financial Insights: Under Armour</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: Under Armour's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -4.75%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Under Armour's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.02% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.01%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Under Armour's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.01%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Under Armour's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 12 Analyst Projections For Under Armour

12 analysts have shared their evaluations of Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Western Alliance, revealing an average target of $85.42, a high estimate of $100.00, and a low estimate of $70.00. This current average has increased by 14.27% from the previous average price target of $74.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1721757650_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Western Alliance is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Bernard von-Gizycki</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$83.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Matthew Clark</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$74.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Casey Haire</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Western Alliance. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Western Alliance compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Western Alliance's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Western Alliance's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WAL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Western Alliance analyst ratings.</a>
<h2>Discovering Western Alliance: A Closer Look</h2>
Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking. Corporate &amp; Other.
<h3>Financial Milestones: Western Alliance's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Western Alliance's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 1.37%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 32.54%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.2%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Western Alliance's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.24%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.1, Western Alliance faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 12 Analysts Discuss Western Alliance Stock

5 analysts have shared their evaluations of Shutterstock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Shutterstock and provided 12-month price targets. The average target is $62.6, accompanied by a high estimate of $65.00 and a low estimate of $58.00. Observing a 0.97% increase, the current average has risen from the previous average price target of $62.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1721757634_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Shutterstock is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Shutterstock. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Shutterstock compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Shutterstock's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Shutterstock's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SSTK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Shutterstock analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Shutterstock: A Closer Look</h2>
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market.
<h3>Shutterstock: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Shutterstock's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -0.45% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Shutterstock's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.52% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Shutterstock's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.02% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Shutterstock's ROA excels beyond industry benchmarks, reaching 1.56%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.11, Shutterstock adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SSTK

Unveiling 5 Analyst Insights On Shutterstock

In the last three months, 7 analysts have published ratings on Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $89.71, a high estimate of $105.00, and a low estimate of $82.00. Surpassing the previous average price target of $85.57, the current average has increased by 4.84%.
<img src="https://www.benzinga.com/files/images/story/2024/1721757625_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Aflac is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$93.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$83.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$82.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Aflac. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aflac compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Aflac's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Aflac's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AFL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Aflac analyst ratings.</a>
<h2>Unveiling the Story Behind Aflac</h2>
Aflac Inc offers supplemental health insurance and life insurance in United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling majority of its policies directly to consumers at their places of work and also reaches out to its customers out of their worksite through digital mediums. The company has two reportable business segments; Aflac Japan which generates the majority of the revenue, and Aflac U.S.
<h3>A Deep Dive into Aflac's Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Aflac showcased positive performance, achieving a revenue growth rate of 12.72% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Aflac's net margin is impressive, surpassing industry averages. With a net margin of 34.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 8.26%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Aflac's ROA excels beyond industry benchmarks, reaching 1.49%. This signifies efficient management of assets and strong financial health.
Debt Management: Aflac's debt-to-equity ratio is below the industry average. With a ratio of 0.34, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Have This To Say About Aflac

Natera's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NYSE">NTRA</a>) short percent of float has risen 15.19% since its last report. The company recently reported that it has 6.38 million shares sold short, which is 5.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.14 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Natera Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721757622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Natera has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Natera's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Natera's peer group average for short interest as a percentage of float is 6.80%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

NTRA

(NTRA) - Analyzing Natera's Short Interest

Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 10 years by 15.73% on an annualized basis producing an average annual return of 26.64%. Currently, Murphy USA has a market capitalization of $10.73 billion. 
Buying $100 In MUSA: If an investor had bought $100 of MUSA stock 10 years ago, it would be worth $1,064.25 today based on a price of $517.77 for MUSA at the time of writing.
<h3>Murphy USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721757618_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MUSA

Here's How Much You Would Have Made Owning Murphy USA Stock In The Last 10 Years

Elevance Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) short percent of float has fallen 4.08% since its last report. The company recently reported that it has 2.19 million shares sold short, which is 0.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Elevance Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721757617_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Elevance Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Elevance Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Elevance Health's peer group average for short interest as a percentage of float is 4.44%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

How Is The Market Feeling About Elevance Health?

Across the recent three months, 5 analysts have shared their insights on Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $233.2, a high estimate of $276.00, and a low estimate of $219.00. Witnessing a positive shift, the current average has risen by 10.1% from the previous average price target of $211.80.
<img src="https://www.benzinga.com/files/images/story/2024/1721757614_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Evercore among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$276.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$219.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$231.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Evercore. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Evercore compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Evercore's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Evercore's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EVR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evercore analyst ratings.</a>
<h2>About Evercore</h2>
Evercore is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,200 employees at the end of 2023, and about 75% of its revenue is derived from the United States.
<h3>Unraveling the Financial Story of Evercore</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Evercore's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 1.52%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Evercore's net margin is impressive, surpassing industry averages. With a net margin of 14.75%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Evercore's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.67% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Evercore's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.55% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Evercore adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Evercore Stock: Analyst Perspectives (5 Ratings)

Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) has outperformed the market over the past 5 years by 12.58% on an annualized basis producing an average annual return of 25.55%. Currently, Ingersoll Rand has a market capitalization of $40.34 billion. 
Buying $1000 In IR: If an investor had bought $1000 of IR stock 5 years ago, it would be worth $3,042.60 today based on a price of $99.95 for IR at the time of writing.
<h3>Ingersoll Rand's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721757613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today

F N B's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) short percent of float has fallen 3.81% since its last report. The company recently reported that it has 8.95 million shares sold short, which is 3.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>F N B Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721757611_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for F N B has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing F N B's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, F N B's peer group average for short interest as a percentage of float is 3.84%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(FNB) - Analyzing F N B's Short Interest

Roth MKM analyst Scott Searle maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and raises the price target from $43 to $44.

CALX

Roth MKM Maintains Buy on Calix, Raises Price Target to $44

Truist Securities analyst Scot Ciccarelli maintains Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) with a Buy and lowers the price target from $183 to $164.

Truist Securities Maintains Buy on Genuine Parts, Lowers Price Target to $164

Known for tapping into the influence of cultural icons, Carma HoldCo Inc. has ventured into the psychedelics space with the launch of Mikeadelics, an innovative home mushroom growing kit under the expanding <a href="https://www.benzinga.com/topic/tyson-2-0">TYSON 2.0</a> brand. This collaboration with Advanced Mycology marks Carma HoldCo&#8217;s first foray into the burgeoning psychedelic industry.
<a href="https://www.benzinga.com/topic/mike-tyson">Mike Tyson</a>, the legendary boxer, co-founder and chief brand officer behind TYSON 2.0, will be on-site for the product launch at the CHAMPS Trade Show in Vegas on July 24. &#8220;Mikeadelics represents a personal journey for me. My interest in <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a> has been well-documented, and I&#8217;m excited to offer a product that makes growing mushrooms accessible to everyone. This kit is a game-changer and makes the process simple and enjoyable,&#8221; he shared in a <a href="https://www.prnewswire.com/news-releases/tyson-2-0-launches-mikeadelics-a-revolutionary-home-grow-mushroom-kit-302203571.html">press release</a>.
Adam Wilks, CEO of Carma HoldCo, emphasized the strategic importance of this launch. &#8220;We are thrilled to introduce Mikeadelics, a product that not only broadens our product offerings but also aligns perfectly with our mission to innovate and deliver unique, authentic experiences to our consumers. This launch also signifies our entry into the psychedelic space in a legal, compliant way, representing a significant milestone for our company.&#8221;
Judd Weiss, president of Advanced Mycology, pointed out the technical advancements of the kit. &#8220;Mycology is a complex and demanding field, but with the TYSON 2.0 Mikeadelics, we&#8217;ve simplified the process. Our unique filter strip technology ensures better airflow and protection against bacteria and mold, making mushroom cultivation accessible to all.&#8221;
<h3 class="wp-block-heading">Innovative Technology And User-Friendly Design</h3>
Mikeadelics simplifies mushroom growing by eliminating the need for specialized equipment. The <a href="https://advancedmyco.com/tyson/">kit</a> includes a TYSON 2.0 Mikeadelics all-in-one grow bag, a detailed instruction booklet, an inoculation data label, an alcohol wipe and a Mylar storage bag with a dry pack for storing dried mushrooms. The kit&#8217;s filter strip technology enhances airflow and protects against contaminants, making it easier for users to maintain sterility. Users simply inject their liquid culture, wait for the mushrooms to form and then harvest. Each grow bag yields approximately 1/2 oz of dry mushrooms, with the potential for two to three harvests per bag.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="994" height="655" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23130427/2-2.png" alt="" class="wp-image-452029" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23130427/2-2.png 994w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23130427/2-2-300x198.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23130427/2-2-768x506.png 768w" sizes="(max-width: 994px) 100vw, 994px" /></figure>
<h3 class="wp-block-heading">Broader Implications For Psychedelic Industry</h3>
The introduction of Mikeadelics clearly represents a shift in the accessibility and normalization of psychedelics for personal use. As more states explore the legalization and regulation of psychedelics, products like Mikeadelics pave the way for broader acceptance and understanding of their benefits. Limited research from the National Institute on Drug Abuse <a href="https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs#drugs-safe">suggests</a> that psychedelics do not typically lead to addiction, and ongoing studies are investigating their potential in treating substance use disorders.
Photo and rendering courtesy of TYSON 2.0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Robix EnvirnTech

News

Latest news for Robix EnvirnTech (OTC:ROBXF) Stock